PDCD1 and cancer: The enriched pathways (p < 0.05, FDR < 0.05) were cancer immunotherapy by PD-1 blockade, IL12-mediated signaling events, downstream signaling in naïve CD8+ T cells, natural killer cell-mediated cytotoxicity, type II interferon signaling (IFNG), interactions between immune cells and microRNAs in tumor microenvironment, granzyme A-mediated apoptosis pathway, and calcineurin-regulated NFAT-dependent transcription in lymphocytes.